Important role of gemcitabine in the treatment of classic Kaposi’s sarcoma

Fable Zustovich, Giuseppe Lombardi, and Davide Pastorelli

Oncologia Medica 1, Istituto Oncologico Veneto, IRCCS, Padua, Italy

Kaposi’s sarcoma (KS) is a rare multifocal lympho-angio proliferative disease related to human herpesvirus 8. Classic KS affects mainly elderly men and early stage treatment is localized with radiotherapy and intralesional vinca alkaloids, while for some aggressive KS variants chemotherapy is needed. To date, various antiblastic drugs including interferon-α, vinblastine, bleomycin, dacarbazine, anthracyclines, and paclitaxel have been studied with an overall response rate of up to 80%. Gemcitabine is widely used in oncology practice and has a good toxicity profile; it is therefore often included in chemotherapy combinations and used as a single agent in the elderly.

We report the case of a 74-year-old man with a diagnosis of classic KS of the lower limbs, who came to our observation with disease progression. KS lesions involved the upper and lower limbs with subcutaneous dissemination to the left thigh accompanied by conspicuous edema (Figures 1 and 2). The patient was heavily pretreated with local radiotherapy, interferon-alfa and multiple lines of chemotherapy including vinblastine, pegylated liposomal doxorubicin, and paclitaxel. We started treatment with gemcitabine at a fixed infusion rate (FIR) of 10 mg/m²/minute on days 1, 8 and 15 every 28 days. The clinical pattern of the lower limbs and left thigh improved dramatically after the first gemcitabine administration and the improvement was confirmed after the end of chemotherapy for a total of 6 courses (Figures 1 and 2). The patient then entered a follow-up program and has been well and without disease progression up to now, 14 months after treatment.

The present case showed a marked and long-lasting response in a patient with heavily pretreated progressive classic KS, using single-agent gemcitabine chemotherapy without any important side effects. A review of the literature worldwide included only one previous report with gemcitabine for the treatment of KS. Brambilla et al.² administered gemcitabine with a standard schedule of 1200 mg/m² over a hypothetic 30-minute infusion (the duration of infusion was not reported in the paper) on days 1 and 8 every 3 weeks to 11 patients with refractory classic KS. The authors obtained an overall response rate of 100% with 1 complete response and 10 partial responses.

We administered gemcitabine at a fixed infusion rate. Prolonged infusion (more than 30 minutes) increased the intracellular rate of gemcitabine’s active metabolites, thereby enhancing the therapeutic and toxic effects.³ Our previous experience in lung cancer patients has shown that gemcitabine doses of up to 1200 mg/m² infused in 120 minutes on days 1, 8 and 15 every 4 weeks are safe.⁴ Two phase II randomized clinical trials evaluated the efficacy of FIR administration of gemcitabine versus the standard 30-minute infusion schedule in non-small cell lung cancer and pancreatic cancer patients. Both studies showed a favorable trend for the FIR modality.⁵ ⁶

Moreover, gemcitabine does not affect the lymphocyte immunoreactive activity in patients with solid tumors and seems to be synergistic with immunotherapy in animal models.⁷ Thus, its combination with interferon-alfa and/or interleukin-2 should be investigated. In conclusion, our findings and the previous findings of Brambilla support the efficacy and safety of gemcitabine in refractory and progressive KS, especially in elderly patients. FIR administration should be preferred and combination with immunotherapy should also be considered.

Key words: Kaposi’s sarcoma, gemcitabine, elderly patient, oncology, chemotherapy.

Correspondence to: Dr Fable Zusto vich, Oncologia Medica 1, Ospedale Busonera, Via Gattamelata 64, 35128 Padova, Italy.
Mobile +39-347-9775504; fax +39-049-8042089; e-mail fable.zustovich@ioveneto.it

Received December 12, 2008; accepted January 13, 2009.
GEMCITABINE AND KAPOSI’S SARCOMA

References


Figure 1 - Cutaneous pattern of the leg before (left) and after (right) gemcitabine treatment.

Figure 2 - MRI with contrast pattern of the left thigh before (left) and after (right) gemcitabine treatment.